ProMIS Neurosciences Inc. Common Shares (ON) PMN
Analyst Ratings
- Consensus
- Buy — 5 Buy · 0 Hold · 0 Sell (5 analysts)
- Avg. Price Target
- $42.50 (+1184.0% upside)
Key Stats
- Today's Range
- $3.21 – $8.53
- 50-Day Range
- $3.21 – $15.46
- 52-Week Range
- $3.21 – $27.40
- Volume
- 1.64 million shs
- Average Volume
- 89K shs
- Market Cap
- $99.36 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.01%
- Days to Cover
- 1.00
About ProMIS Neurosciences Inc. Common Shares (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
Related Stocks
Compare head-to-head: PMN vs LLY·PMN vs JNJ·PMN vs ABBV·PMN vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.